| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Phase 2a data readout example | Phase 2a | — | Subscribe to access the data. | Biologics | Endocrine System |
Recent Updates
Recently added Catalysts
Skye Bioscience, Inc.$0.69
+0 (+0.41%)
D 35Pipeline Score Overvalued Pharma · Clinical
Market Cap
29.14 M
EPS
-1.45
P/E Ratio
-
Value Trade
126.48 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
7.94 M
Operating CF
-8.56 M
Total Assets
19.42 M
Total Liabilities
10.40 M
Equity
9.01 M
D/E Ratio
12,345
-4.68 %
Week
-0.71 %
1 Month
4.97 %
3 Month
-33.66 %
6 Month
-97.3 %
5 Year
-99.89 %
All Time
Cash Data
Cash Position
17.11 M
Monthly Burn
2.85 M
Runway
4.2 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
184.95 K
52 Week Range
0.57 - 5.75
% held by Insiders
34.65 %
% held by Institutions
12.64 %
Enterprise Value
12.35 M
Total Shares
35.14 M
Short %
4.1 %
Float Shares
23.16 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Skye Bioscience, Inc.
289Total events
6Upcoming
59Tier-1 (high impact)
2015 – 2026Coverage
Upcoming catalysts 6
Event history 283
Q3 2026
◆Full ResultsNimacimabClinical Data
Full topline reporting of Phase 2a extension data including monotherapy and 13-week follow-up
obesitysource ↗
Q3 2026
◆Topline ReadoutNimacimabClinical Data
CBeyond Phase 2a topline results to 52 weeks including 13-week off-therapy follow-up expected Q3 2026
obesitysource ↗
Q3 2026
◆Trial InitiationNimacimabTrial
Phase 2b (CBeyond 2) trial launch targeted for Q3 2026
obesitysource ↗
May 20, 2026
▲Safety Data UpdateNimacimabClinical Data
CRC approved opening of Cohort 2 based on favorable safety data from first four participants in Cohort 1
obesitysource ↗
May 18, 2026
May 12, 2026
▲Trial InitiationNimacimabTrial
Initiated enrollment of Cohort 1 of CBeyond Expansion Study
obesitysource ↗
May 11, 2026
▲Trial InitiationNimacimabTrial
Initiated enrollment of Cohort 1 of CBeyond Expansion Study
obesitysource ↗
May 11, 2026
▲Partnership / LicenseNimacimabCorporate
Engaged Lilly Catalyze360 for strategic guidance on TPP and Phase 2b trial design
obesitysource ↗
Apr 16, 2026
◆Oral PresentationNimacimabPresentation
Presentation at GLP-1-Based Therapeutics Summit
obesitysource ↗
Apr 2, 2026
▲First Patient DosedNimacimabTrial
First patient dosed in Part C expansion study of nimacimab higher-dose IV cohorts
obesitysource ↗
Drug Pipeline Intelligence
D35
Pipeline Score $19M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.7x
rNPV / MCap Top 47%
Micro Cap (rank 484 of 911)
Percentile RankSkye Bioscience, Inc. faces pipeline headwinds (35/100), with $1.7B risk-adjusted pipeline value, led by Nimacimab in Obesity (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nimacimab Monoclonal antibody | Obesity | Phase 2 | NCT06577090 | 33% | $1.5B | ACTIVE NOT_RECRUITING | 136 | SLOW | B (72) | Feb 28, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
nimacimab | obesity and related conditions | Phase 2b | 2026-05-12 | approximately 3% incremental weight-loss benefit versus semaglutide alone at 26 weeks; 22.3% mean weight loss at 52 weeks Read More | UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update Read More | |
nimacimab | obesity and related conditions | Phase 2b | 2026-05-12 | approximately 3% incremental weight-loss benefit versus semaglutide alone at 26 weeks; 22.3% mean weight loss at 52 weeks Read More | UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update Read More | |
nimacimab | obesity and related conditions | Phase 2b | 2026-05-12 | approximately 3% incremental weight-loss benefit versus semaglutide alone at 26 weeks; 22.3% mean weight loss at 52 weeks Read More | UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SKYE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SKYE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SKYE▲ +6%on this news
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
Skye Bioscience has announced the unanimous approval by its Cohort Review Committee to open enrollment for Cohort 2 in the CBeyond Part C Expansion Study. This decision is based on favorable safety data from the initial four participants treated in Cohort 1. The study is focused on the safety of nimacimab monotherapy, with a comparison against a placebo. The initial findings have shown no reported neuropsychiatric adverse events, allowing for a dosage escalation to 600 mg IV in the new cohort.
Read more →SKYE▼ -7.6%on this news
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Skye Bioscience reported its Q1 2026 financial results, highlighting the initiation of the CBeyond Expansion Study and the upcoming review by the Cohort Review Committee. The company aims to advance nimacimab as a complementary therapy for obesity and related conditions. Financially, Skye holds $17.1 million in cash, which is expected to support operations through Q4 2026, despite a net loss of $12.5 million.
Read more →SKYESkye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Skye Bioscience reported its Q1 2026 financial results, highlighting the initiation of the CBeyond Expansion Study and strategic partnerships for the development of nimacimab. The company aims to prepare for a Phase 2b trial, with topline data expected by Q4 2026. Despite a net loss, Skye remains focused on advancing its clinical programs.
Read more →SKYESkye Bioscience Presenting at GLP-1-Based Therapeutics Summit
Skye Bioscience will present at the GLP-1-Based Therapeutics Summit in Boston on April 16, 2026. The presentation will focus on their drug nimacimab, a monoclonal antibody designed to treat obesity without central nervous system side effects. The company is conducting a Phase 2a trial to evaluate the efficacy of nimacimab in combination with GLP-1 agonists.
Read more →SKYESkye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Skye Bioscience has initiated treatment for the first patient in its Part C expansion study of nimacimab as part of the Phase 2a trial. This study aims to evaluate higher doses of nimacimab to inform dose selection for a potential Phase 2b trial. Previous studies have shown promising weight loss results when combined with semaglutide, and the company has received regulatory feedback from the FDA. However, enrollment for the second dosing cohort is contingent on the safety review of the first cohort's participants.
Read more →SKYE▲ +11%on this news
2025 Year-end & Q4 Financial Results and Update
The article discusses the financial results for the year-end and Q4 of 2025 for SKYE. It mentions the publication date of March 10, 2026, and includes references to related documents such as a news release and a conference call presentation. However, specific financial details or insights are not provided in the text.
Read more →SKYE▲ +10.3%on this newsshared move
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Skye Bioscience reported its financial results for Q4 and full year 2025, detailing key developments in its programming aimed at obesity treatment. The company has initiated a higher-dose CBeyond Expansion Study targeting improved safety and pharmacokinetics for nimacimab, alongside promising results from its Phase 2a trial in combination with semaglutide leading to significant weight loss. Skye is utilizing FDA feedback to refine its Phase 2b trial design, suggesting a disciplined approach to dosage and effectiveness evaluation. Continued advancements in manufacturing processes support the potential for nimacimab's commercial supply and improved patient accessibility.
Read more →SKYESkye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
Skye Bioscience, a clinical-stage biotechnology company, will announce its 2025 financial results and business update on March 10, 2026. The announcement will be followed by a conference call to discuss the results. Skye is actively developing therapeutics for obesity, including a Phase 2a trial for nimacimab, a novel antibody.
Read more →SKYE▼ -7.9%on this news· ran to -21% by day 3
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
Skye Bioscience announced positive interim results from the Phase 2a CBeyond study, showing that patients receiving nimacimab in combination with semaglutide achieved a mean weight loss of 22.3% after 52 weeks. The therapy was well tolerated, with no serious adverse events reported. The results suggest potential for further weight loss with optimized dosing in future trials.
Read more →SKYE▼ -7.9%on this news· ran to -21% by day 3shared move
Developing Innovative Medicines to Treat Obesity and Other Metabolic Diseases February 2026 Nasdaq: SKYE 2 02 6 Sk ye B io sc ie nc e, In c. This presentation ("Presentation") has been prepared solely for general infor
Skye Bioscience, Inc. is advancing its innovative medication, nimacimab, aimed at treating obesity and metabolic diseases. Featuring a combination therapy with semaglutide, recent Phase 2a data show nimacimab resulted in significant weight loss outcomes, improving treatment tolerability. However, the therapy remains in investigational phases pending regulatory review, and the company has noted potential risks linked to capital constraints and clinical trials.
Read more →SKYESkye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
Skye Bioscience presented findings on its peripherally-restricted CB1 inhibitor, nimacimab, at the Keystone Obesity Conference. The studies suggest that nimacimab combined with lower doses of incretin agonists could provide a safer and effective treatment for obesity. The company is conducting a Phase 2a trial to further evaluate nimacimab's efficacy and safety.
Read more →SKYENimacimab Enhances Incretin Therapies in DIO Mouse Model
At the Keystone conference, it was reported that Nimacimab significantly enhances weight loss when used with tirzepatide, even at lower doses. The treatment led to durable weight loss post-discontinuation and improved rebound profiles. Notably, caloric restriction was not the main factor driving the weight loss associated with Nimacimab.
Read more →SKYESkye Bioscience to Present Poster at Keystone Obesity Conference
Skye Bioscience will present a poster on its CB1-inhibitor antibody, nimacimab, at the Keystone Obesity Conference. The presentation will explore nimacimab's efficacy alone and in combination with tirzepatide in a mouse model of diet-induced obesity. This innovative approach aims to limit neuropsychiatric side effects associated with traditional CB1-targeting drugs. Skye is also conducting a Phase 2a clinical trial for nimacimab in obesity.
Read more →SKYE▼ -5.6%on this newsshared move
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Skye Bioscience, Inc. is facing a class action lawsuit from investors represented by the Schall Law Firm for alleged violations of the Securities Exchange Act. The lawsuit claims the company made false statements about its drug candidate, nimacimab, which was less effective than advertised. Investors who acquired Skye's securities within a specified period are encouraged to participate in the case. The firm is reminding potential plaintiffs that they must act before the lawsuit's certification.
Read more →SKYE▼ -5.6%on this newsshared move
SKYE BIOSCIENCE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th
Skye Bioscience, Inc. is facing a class action lawsuit filed in the Southern District of California, alleging that the company made materially false and misleading statements about its drug, nimacimab, between November 2024 and October 2025. The complaint claims that the effectiveness of nimacimab was overstated, leading investors to suffer significant losses when its ineffectiveness became apparent. Following a press release on October 6, 2025, which revealed that the drug did not meet its primary objectives in clinical trials, Skye's stock price dropped dramatically by 60%. Investors have until January 16, 2026, to apply to be lead plaintiffs in the lawsuit.
Read more →SKYE▼ -5.6%on this newsshared move
SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE
Rosen Law Firm has issued a reminder to investors of Skye Bioscience, Inc. regarding a class action lawsuit with a January 16, 2026, deadline. The lawsuit addresses allegations of misleading statements made by the defendants concerning Skye's performance and the efficacy of its product nimacimab. Investors who purchased securities during the specified class period might be eligible for compensation without upfront costs. Potential class members are encouraged to secure experienced legal counsel to represent them.
Read more →SKYESKYE DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE
Rosen Law Firm has reminded investors of Skye Bioscience, Inc. about the January 16, 2026 deadline to join a securities class action. The action pertains to allegations that the company made misleading statements regarding the effectiveness and prospects of its product, nimacimab, during a specified period. A class action lawsuit has already been initiated, and interested investors are encouraged to secure their counsel before the deadline to potentially seek compensation.
Read more →SKYESkye Bioscience, Inc. (NASDAQ: SKYE) Securities Class Action: Johnson Fistel Reminds Investors of January 16 Deadline to Seek Lead Plaintiff Appointment
A class action lawsuit has been filed against Skye Bioscience on behalf of investors who acquired its securities from November 2024 to October 2025. The lawsuit claims that the company made materially false and misleading statements regarding its drug candidate nimacimab, which allegedly proved less effective than advertised. Investors are encouraged to seek appointment as lead plaintiff by the January 16, 2026 deadline to recover losses incurred from these misrepresentations. The firm representing the plaintiffs, Johnson Fistel, is known for handling securities class actions and has successfully recovered significant amounts for investors in the past.
Read more →SKYESKYE BIOSCIENCE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th
A class action lawsuit has been filed against Skye Bioscience in the Southern District of California on behalf of shareholders who purchased its securities between November 4, 2024, and October 3, 2025. The lawsuit alleges that Skye made false and misleading statements about the efficacy and prospects of nimacimab, which did not achieve its primary endpoint of weight loss during a recent clinical trial. Following the release of disappointing trial results, Skye's stock saw a drastic decline of 60%, closing at $1.90 per share. Investors have until January 16, 2026, to apply as lead plaintiffs in the case.
Read more →SKYESkye Provides 2026 Corporate Outlook
Skye Bioscience has outlined its corporate outlook for 2026, focusing on advancing its lead candidate, nimacimab, through various clinical trials and milestones. Key upcoming events include a data update on Phase 2a trials expected in Q1 2026 and the design of a Phase 2b trial targeting combination therapies. Preliminary results indicate the potential for nimacimab to complement existing treatments for obesity, showcasing additive effects when used with semaglutide. Despite positive indicators, future progress depends on adequate funding and execution of planned clinical studies.
Read more →SKYE▼ -6.7%on this newsshared move
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
Faruqi & Faruqi, LLP is investigating potential claims against Skye Bioscience on behalf of investors who may have suffered losses due to misleading statements regarding the efficacy of nimacimab. The investigation follows a significant drop in Skye's stock price after clinical trial results indicated that the treatment did not achieve its primary endpoint. Investors are reminded of a deadline to seek roles in a federal securities class action against the company, further complicating Skye's legal and financial situation.
Read more →SKYE▼ -6.7%on this newsshared move
Skye Bioscience, Inc. Class Action: Levi & Korsinsky Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 – SKYE
Skye Bioscience, Inc. is facing a class action securities lawsuit related to alleged fraud that affected investors between November 4, 2024, and October 3, 2025. The lawsuit claims that the company's lead product candidate, nimacimab, was misrepresented, leading to inflated expectations regarding its efficacy and market prospects. Affected investors have until January 16, 2026, to apply for lead plaintiff status, although compensation may be available without incurring costs. The lawsuit highlights concerns over transparency in the company's communications to investors.
Read more →SKYE▼ -6.7%on this newsshared move
SKYE FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE
Rosen Law Firm has announced a reminder for investors of Skye Bioscience, Inc. regarding an ongoing securities class action. Investors who purchased securities during the defined Class Period from November 4, 2024, to October 3, 2025, are encouraged to secure legal counsel by the January 16, 2026, deadline. The lawsuit claims that the company made false statements concerning the efficacy of its drug, nimacimab, which has resulted in investor losses. Potential plaintiffs can join the class action without upfront fees through a contingency fee arrangement.
Read more →SKYE▲ +17.7%on this news· ran to +29% by day 1shared move
SKYE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Skye Bioscience, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Skye Bioscience, Inc. on behalf of investors who acquired securities during the specified Class Period. The lawsuit alleges that Skye made materially false and misleading statements about its product, nimacimab, particularly regarding its effectiveness and clinical prospects. Following the announcement of unimpressive trial results, Skye's stock price experienced a significant decline of 60%. Investors have until January 16, 2026, to apply to be lead plaintiff in the case.
Read more →SKYEWorking with Halozyme ENHANZE® Technology for Higher Dosing
Skye Bioscience has published an article discussing their collaboration with Halozyme to utilize ENHANZE® technology for higher dosing. This technology aims to enhance drug delivery and improve patient outcomes. The article highlights the potential benefits of this partnership in the bioscience field, particularly concerning obesity treatment.
Read more →SKYEUsing Arecor’s Arestat Technology to Increase Drug Dosing
Skye Bioscience has announced the use of Arecor's Arestat technology to enhance drug dosing. This development was published on January 4, 2026. The article does not provide further details on the implications or applications of this technology in drug development.
Read more →SKYEUnlocking Solutions to Deliver Higher Doses
The article discusses Skye Bioscience's efforts to develop solutions for delivering higher doses of treatments. It highlights the importance of addressing dosing challenges in bioscience, particularly in the context of obesity. The publication date indicates a recent focus on advancements in this area.
Read more →SKYECharacterizing/Advancing Higher-exposure Dosing
Skye's Project Ascend is a 90-day initiative focused on validating higher-exposure dosing for nimacimab. The project aims to enhance the clinical and translational evidence supporting the role of peripheral CB1 inhibition in treating obesity. This effort represents a significant step forward in addressing obesity through innovative dosing strategies.
Read more →SKYESkye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights – SKYE
Skye Bioscience, Inc. is facing a class action lawsuit regarding securities fraud from shareholders who purchased stock between November 4, 2024, and October 3, 2025. The lawsuit alleges that the company made false or misleading statements about its lead product candidate, nimacimab, claiming it was more effective than it actually is. Given these allegations, shareholders are encouraged to register with the Gross Law Firm before the January 16, 2026, deadline for lead plaintiff appointments and updates.
Read more →SKYE▼ -7.6%on this newsshared move
CEO 2025 Year in Review
In the 2025 Year in Review, CEO Punit Dhillon outlines Skye Bioscience's achievements over the past year and shares insights into the strategic plans for 2026. The review emphasizes the company's commitment to advancing in the bioscience sector, particularly in addressing obesity. Skye aims to build on its successes as it moves into the new year.
Read more →SKYESKYE LAWSUIT ALERT: The Gross Law Firm Notifies Skye Bioscience, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
The Gross Law Firm has issued a notice to shareholders of Skye Bioscience, Inc. regarding a class action lawsuit related to the company's lead product, nimacimab. The lawsuit claims that the defendants provided materially false statements and misrepresented the drug's effectiveness and prospects. The class period for affected shareholders spans from November 4, 2024, to October 3, 2025, with a deadline for lead plaintiff applications set for January 16, 2026. Shareholders are encouraged to register to participate in the case without any cost or obligation.
Read more →SKYESKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Skye Bioscience, Inc. for alleged violations of federal securities laws. The lawsuit seeks damages for investors who acquired Skye securities during a specified Class Period. Accusations include misleading statements regarding the effectiveness of nimacimab and its prospects. Affected investors have until January 16, 2026, to request to be appointed as lead plaintiffs in the case.
Read more →SKYESKYE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
Faruqi & Faruqi, LLP has initiated an investigation into Skye Bioscience, following claims of securities law violations. The investigation arises from allegations that the company's drug, nimacimab, was less effective than reported, leading to overstated clinical and commercial prospects. Following the announcement of disappointing clinical trial results, Skye's stock experienced a significant price drop of 60%. Investors are reminded of the upcoming deadline to seek lead plaintiff status in the ongoing federal class action lawsuit.
Read more →SKYE▼ -5.2%on this news· ran to -19% by day 3shared move
Skye Bioscience, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights – SKYE
Skye Bioscience, Inc. is facing a class action lawsuit filed by Levi & Korsinsky, LLP, alleging securities law violations. The lawsuit claims that the company made false statements regarding the effectiveness of its lead product candidate, nimacimab, which impacted the investors adversely. Investors affected by the alleged misrepresentation have until January 16, 2026, to seek appointment as lead plaintiff. The lawsuit is tied to events that occurred between November 4, 2024, and October 3, 2025.
Read more →SKYE▼ -5.2%on this newsshared move
Skye Bioscience, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SKYE
Skye Bioscience, Inc. is embroiled in a class action securities lawsuit initiated by Levi & Korsinsky, LLP, affecting investors who suffered losses between November 4, 2024, and October 3, 2025. The lawsuit alleges that the company misrepresented the effectiveness and potential of its lead product candidate, nimacimab, resulting in misleading public statements. Investors are being encouraged to contact the law firm for more information, with a deadline of January 16, 2026, for those wishing to be appointed as lead plaintiff. There are no costs for class members to participate in the lawsuit.
Read more →SKYESkye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SKYE
Skye Bioscience, Inc. is facing a class action lawsuit due to alleged violations of securities laws. The DJS Law Group is leading the lawsuit, asserting that Skye made false claims about the efficacy of its drug nimacimab. Affected shareholders are encouraged to participate in the case to pursue recovery for their losses. The class period for the lawsuit is from November 4, 2024, to October 3, 2025, with a deadline for participation set for January 16, 2026.
Read more →SKYESKYE Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Skye Bioscience, Inc. Class Action Lawsuit
Skye Bioscience, Inc. is facing a class action lawsuit due to allegations that it misled investors about its lead drug candidate, nimacimab. The complaint specifically states that the company failed to disclose the drug's lack of effectiveness and overstated its clinical prospects. As a result of this news, Skye's stock price experienced a significant drop of 60%. Shareholders during the class period are encouraged to participate in the lawsuit against the company.
Read more →SKYESKYE Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Skye Bioscience, Inc.
Robbins LLP has alerted investors about a class action lawsuit against Skye Bioscience, Inc. (SKYE) for allegedly misleading shareholders about the effectiveness of its lead drug candidate, nimacimab. The lawsuit claims that the company's representations about nimacimab's performance were overstated, particularly regarding its prospects for treating obesity and metabolic diseases. Following the release of disappointing Phase 2a trial results on October 6, 2025, Skye's stock price dropped significantly, indicating investor concern over the company's future. Shareholders eligible to participate in the class action must file their papers by January 16, 2026.
Read more →SKYEThird Quarter 2025 Financials & Operational Update
The article provides a brief update on the financial and operational status of SKYE for the third quarter of 2025. It mentions the publication date and includes references to a conference call and related documents. However, it lacks detailed financial data or operational insights.
Read more →SKYESkye Bioscience Reports Third Quarter 2025 Financial Results and Business Update
Skye Bioscience reported its third-quarter financial results for 2025, highlighting progress in its CBeyond Phase 2a obesity trial. The company is optimistic about nimacimab's potential as a treatment for obesity, particularly in combination with GLP-1R agonists. Upcoming biomarker data is expected to provide further insights into the drug's efficacy. However, the company faces challenges related to funding and the uncertainties of clinical trial outcomes.
Read more →SKYEObesityWeek Presentation: Additional P2a Study Data
The article discusses the presentation of additional Phase 2a study data for nimacimab at the ObesityWeek Medical Conference. This presentation highlights the ongoing research efforts surrounding the treatment of obesity. The event serves as a platform for sharing significant advancements in the field.
Read more →SKYE▲ +6.3%on this newsshared move
Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
Skye Bioscience will present late-breaking data at ObesityWeek 2025, showcasing the effectiveness of nimacimab, a CB1 inhibitor, in reducing rebound weight gain when combined with semaglutide. The Phase 2 study revealed that participants receiving the combination maintained significant weight loss compared to those on semaglutide alone. The findings suggest nimacimab's potential role in obesity treatment.
Read more →SKYE▲ +6.3%on this newsshared move
Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025
Skye Bioscience, a clinical-stage biotechnology company, will announce its third quarter 2025 financial results and provide a business update on November 10, 2025. A conference call is scheduled for the same day, and investors can access the webcast on the investor relations website. Additionally, Skye will present at the Stifel 2025 Healthcare Conference on November 13 and will be available for one-on-one meetings.
Read more →SKYE▼ -60%on this news
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
Skye Bioscience announced topline results from its Phase 2a CBeyond™ trial of nimacimab, revealing that while the monotherapy did not achieve the primary weight loss endpoint, the combination with semaglutide resulted in significant weight loss. The study indicated a favorable safety profile for nimacimab, with no increase in adverse events. Further evaluations for higher dosing are planned to optimize treatment efficacy.
Read more →SKYE▼ -60%on this newsshared move
CBeyond P2a Data: Nimacimab as Mono and Combination Therapy
CBeyond has released topline data from its Phase 2a trial, indicating that nimacimab is effective both as a standalone treatment and in combination with semaglutide, a GLP-1 therapeutic. The results highlight significant weight loss, along with favorable tolerability and safety profiles. This data may support further development of nimacimab in obesity management.
Read more →SKYESkye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
Skye Bioscience presented Phase 1b data for nimacimab at the EASD Annual Meeting, highlighting its safety and tolerability in subjects with MASLD. The study reported no serious adverse events and mild gastrointestinal side effects. The findings suggest nimacimab's potential role in treating metabolic diseases, paving the way for further studies, including a Phase 2a obesity trial.
Read more →SKYENimacimab P1b Safety and Tolerability Data
At the EASD 2025 conference, Skye presented findings from a Phase 1b study on nimacimab. The data focused on the safety, tolerability, and pharmacokinetics of the drug in patients with metabolic associated steatotic liver disease (MASLD). The results indicate a positive profile for nimacimab after repeat dosing.
Read more →SKYEImproving Obesity Health Outcomes via CB1 Inhibition
Skye Bioscience's Chief Medical Officer, Puneet Arora, MD, MS, FACE, highlights the role of CB1 receptors in energy modulation. The discussion emphasizes that targeting these receptors could improve obesity health outcomes by promoting a healthier metabolic state rather than merely suppressing appetite.
Read more →SKYEGLP-1 Therapies: Breakthroughs vs Breakdowns
Skye Bioscience's Chief Medical Officer, Puneet Arora, MD, discusses the advantages of GLP-1 therapies, particularly their role in hunger suppression and fat reduction. The article also emphasizes the importance of complementary treatments to cater to the diverse needs of patients. This comprehensive review highlights the potential breakthroughs in incretin drug therapies.
Read more →SKYEThe Defended Biological State of Obesity
The article features Puneet Arora, Chief Medical Officer of Skye Bioscience, discussing the biological mechanisms that contribute to obesity. He highlights the body's natural inclination to retain fat and the challenges faced in developing effective therapeutic drugs to combat this issue. The insights aim to shed light on the complexities of obesity treatment.
Read more →SKYEThe Detriment of Deranged Metabolism
The article features Skye's Chief Medical Officer, Puneet Arora, discussing the negative impacts of excess energy storage in the body, particularly how it contributes to obesity and related health issues. The focus is on the detrimental effects of deranged metabolism and the need for awareness in addressing these conditions. The insights aim to foster a better understanding of metabolic health.
Read more →SKYEThe Metabolically Healthy Human
Skye Bioscience's CMO discusses the human metabolic system in a healthy state, emphasizing its role in energy management and fat storage. The article outlines how the body functions optimally when metabolically healthy. This insight is crucial for understanding overall health and wellness.
Read more →SKYE▲ +6.7%on this news
Review: Preclinical Data and Unmet Needs for Obesity Therapeutics
Skye's CEO and CMO have gathered insights from three obesity specialists regarding the upcoming Phase 2a clinical trial data for their CBeyond program. The discussion also highlights new preclinical results that may address significant unmet needs in obesity therapeutics. This collaboration aims to improve treatment strategies for obesity.
Read more →SKYE▲ +7.8%on this news· ran to +18% by day 3shared move
Reviewing Component Mechanisms of Peripheral CB1 Inhibitor Antibody
The article features an in-depth discussion by Skye's CMO and CSO on the unique mechanistic components of nimacimab, a peripherally-restricted CB1-inhibiting antibody. This review highlights the innovative aspects of the drug and its potential implications in therapeutic applications. The insights provided aim to differentiate nimacimab from other treatments in the market.
Read more →SKYEComparing Weight Loss/Rebound between Distinct CB1 Inhibitors
The article discusses a study comparing the weight loss effects and rebound dynamics of nimacimab, a CB1 inhibitor, against other small molecule inhibitors. It highlights the advantages of nimacimab in promoting weight loss while minimizing rebound effects. This research contributes to understanding the efficacy of different CB1 inhibitors in weight management.
Read more →SKYE▲ +11.6%on this news· ran to +23% by day 3shared move
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
Skye Bioscience reported promising results from preclinical studies of nimacimab, a CB1-inhibiting monoclonal antibody, showing it can achieve superior weight loss and maintain results better than monlunabant. The studies also indicated that combining nimacimab with tirzepatide enhances weight loss while limiting rebound effects after treatment cessation. These findings position nimacimab as a potential key player in obesity therapies.
Read more →SKYE▲ +11.6%on this news· ran to +23% by day 3shared move
Assessing Additive Effects when Combined with Tirzepatide
The research published on September 4, 2025, evaluates the combined effects of nimacimab and tirzepatide. It highlights the advantages of this combination over using either drug alone, particularly regarding weight rebound and maintenance. The findings suggest a positive outlook for patients seeking effective weight management solutions.
Read more →SKYE▲ +11.6%on this news· ran to +23% by day 3shared move
Assessing Nimacimab + Incretin Combination Weight Loss Dynamics
The research on nimacimab combined with incretin reveals that weight loss is not solely due to caloric deficit. It also explores the dynamics of weight rebound and the benefits of maintaining weight loss. This study contributes valuable insights into the mechanisms behind the efficacy of this combination therapy.
Read more →SKYESkye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
Skye Bioscience has completed the 26-week treatment phase of its Phase 2a CBeyond™ clinical trial for nimacimab, a CB1 inhibitor antibody aimed at treating obesity. The trial's primary endpoint is to evaluate weight loss and safety compared to placebo. Skye plans to report topline data in late Q3 or early Q4 of 2025, with an extension study also underway.
Read more →SKYEA Look at Manufacturing Nimacimab
The article features an interview with Tu Diep, COO of Skye Bioscience, discussing the complexities of manufacturing Nimacimab for commercial sale. It highlights the importance of adhering to FDA requirements and the challenges faced in the drug manufacturing process. This insight reflects the company's dedication to meeting regulatory standards and ensuring product quality.
Read more →SKYESkye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
Skye Bioscience will host a virtual KOL event on September 4 to discuss upcoming topline results from the Phase 2a CBeyond trial of nimacimab, a new treatment for obesity. The event will feature key opinion leaders who will address safety, tolerability, and the potential impact of the drug on obesity treatment. Insights shared may guide the drug's progression to Phase 2b development.
Read more →SKYESkye Bioscience to Participate in Upcoming Investment and Medical Conferences
Skye Bioscience, a clinical-stage biotechnology company, announced its participation in upcoming investment and medical conferences. The company is developing nimacimab, a therapeutic for obesity, currently in a Phase 2a clinical trial. This trial assesses nimacimab's efficacy both alone and in combination with a GLP-1R agonist. Skye aims to unlock new therapeutic pathways for metabolic health.
Read more →SKYE▼ -8.7%on this news
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
Skye Bioscience has reported its second-quarter financial results for 2025, highlighting the ongoing patient enrollment in its CBeyond™ Phase 2a obesity trial and upcoming milestones. The independent Data Safety Monitoring Committee has completed reviews of the trial with no concerns noted. Preclinical data suggests that nimacimab may enhance weight loss outcomes and maintain weight loss better than existing therapies. Skye's financial outlook remains positive, with sufficient cash reserves to support operations and milestones through early 2027.
Read more →SKYESkye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
Skye Bioscience, a clinical-stage biotechnology company, is scheduled to announce its second quarter 2025 financial results and business update on August 7, 2025. The conference call will take place at 1:30 p.m. PT/4:30 p.m. ET and will be accessible via the company's Investor Relations website. In addition to financial results, Skye is focused on developing new therapeutics for obesity and metabolic disorders, including a Phase 2 trial for its drug nimacimab. The company's approach emphasizes innovative biologic targets for effective treatment development.
Read more →SKYE▲ +12.4%on this news
Diet, Not Lack of Exercise, Is Driving Obesity
The article discusses how dietary changes are the main contributor to rising obesity rates, rather than a lack of exercise. It emphasizes the significance of what people consume over their physical activity levels. This perspective aims to reshape the understanding of obesity management.
Read more →SKYE▼ -6.6%on this news
Proven, Complementary Weight Loss Mechanism: CB1 Inhibition
The article discusses Nimacimab's mechanism of action as a CB1 inhibitor, highlighting its peripheral targeting that promotes fat mass loss without entering the brain. This unique approach positions Nimacimab to address limitations of existing weight loss medications. The findings suggest a promising alternative for weight management.
Read more →SKYEHeterogeneous Needs Not Fulfilled by Approved Incretin Drugs Alone
Tu Diep, COO of Skye Bioscience, addresses the evolving perception of obesity from a personal lifestyle choice to a recognized disease. This shift necessitates new treatment paradigms and highlights the inadequacies of current incretin drugs. The discussion emphasizes the importance of adapting treatment approaches to meet diverse patient needs.
Read more →SKYE▲ +11.5%on this news· ran to +23% by day 1shared move
The Bio Report Podcast: Obesity Therapy Unmet Needs
The podcast explores the challenges in obesity treatments, particularly issues like tolerability, muscle loss, and weight rebound after stopping therapy. It discusses the potential of peripheral CB1 inhibition as a solution to these unmet needs, aiming to enhance patient outcomes in obesity management.
Read more →SKYE▲ +32.9%on this news· ran to +97% by day 3
Nimacimab Promotes Metabolic Homeostasis
Skye presented a poster at the American Diabetes Association conference showcasing nimacimab's effectiveness in promoting weight reduction and improving metabolic health. The findings indicate significant enhancements in body composition and hormonal profiles, contributing to the restoration of metabolic homeostasis. These results highlight the potential of nimacimab in metabolic health management.
Read more →SKYE▲ +32.9%on this news· ran to +97% by day 3shared move
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions
Skye Bioscience launched a video series detailing the development of its anti-obesity drug, nimacimab, showcased at the American Diabetes Association's 85th Scientific Sessions. The presentations emphasize nimacimab's unique mechanism of action, targeting peripheral CB1 receptors, which could offer significant benefits without the neuropsychiatric side effects associated with existing treatments. Promising data from preclinical studies were discussed, highlighting the potential for nimacimab to provide weight loss and metabolic benefits. The company aims to advance its clinical activities and explore market opportunities for this innovative therapy.
Read more →SKYE▲ +32.9%on this news· ran to +97% by day 3shared move
Diet-induced Obesity Model Weight Loss and Biomarker Data
The article discusses a presentation at an obesity-related medical conference highlighting nimacimab's unique features. It emphasizes significant weight loss results from a pre-clinical diet-induced obesity model. Additionally, new biomarker data was introduced, showing notable reductions in inflammation and liver steatosis associated with obesity.
Read more →SKYE▲ +32.9%on this news· ran to +97% by day 3shared move
Skye + Obesity Specialists Discuss Non-incretin Therapeutics
Skye executives participated in a discussion hosted by Evercore healthcare analysts, focusing on non-incretin therapeutics for obesity care. They highlighted the significance of the CB1 pathway and the role of nimacimab in peripheral CB1 blockade. The conversation emphasized the need for solutions beyond the GLP-1 era.
Read more →SKYE▲ +32.9%on this news· ran to +97% by day 3shared move
Revisiting the Potential Role of a Restricted CB1 Inhibitor
Skye's recent update emphasizes its advancements in obesity drug development. The company is focusing on an allosteric modulating antibody that prioritizes fat metabolism and safety. This strategic positioning aims to enhance long-term care for patients. The video series highlights these developments and their potential impact.
Read more →SKYENimacimab: Designed to Offer Distinct Capabilities
The article reviews Skye's CB1 inhibitor, Nimacimab, highlighting its unique properties compared to existing anti-obesity drugs. It emphasizes the advantages of Nimacimab over the incretin class and small-molecule CB1 inhibitors. Recent preclinical data is discussed, showcasing the potential efficacy of this innovative treatment.
Read more →SKYEAssessing the Effect of Nimacimab’s Mechanistic Differences
The article discusses Skye's CBeyond Trial, which evaluates the efficacy of nimacimab in promoting weight loss compared to a placebo. The trial also investigates the effects of combining nimacimab with semaglutide versus semaglutide alone. This research aims to understand the mechanistic differences of nimacimab in treating obesity.
Read more →SKYEConsidering the Opportunity for a Differentiated Target Product Profile
The article discusses insights from obesity physicians regarding the potential for a non-GLP1 obesity therapeutic. It emphasizes the differentiated target product profile of nimacimab, a peripherally-restricted CB1 inhibitor. This presents a unique opportunity in the obesity treatment landscape, suggesting a shift away from traditional GLP1 therapies.
Read more →SKYESkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions
Skye Bioscience, Inc. announced that it has been selected to present expanded preclinical data on nimacimab at the American Diabetes Association's 85th Scientific Sessions. The presentations will include significant findings on the therapeutic potential of nimacimab, a peripherally restricted CB1 inhibitor, in promoting metabolic health and weight loss. Scheduled forums include panel discussions and poster presentations detailing how nimacimab works in diet-induced obesity mouse models. The conference will run from June 20 to 23, 2025, in Chicago, Illinois.
Read more →SKYE▼ -6.3%on this news
Skye Bioscience to Participate in Upcoming Investment Conferences
Skye Bioscience, Inc. announced its participation in upcoming healthcare investment conferences, including the Jefferies Global Healthcare Conference and the Sachs European BioPharma Obesity Innovation Forum. The company is focused on developing therapeutic pathways for obesity and metabolic health disorders, with its ongoing Phase 2 clinical trial for the drug nimacimab. This trial assesses nimacimab's efficacy and safety both as a standalone treatment and in combination with a GLP-1 receptor agonist. Skye aims to leverage biologic targets with strong human proof of mechanism in its therapeutic development.
Read more →SKYE▲ +15%on this newsshared move
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
Skye Bioscience has partnered with Arecor Therapeutics to develop a higher concentration formulation of its obesity candidate, nimacimab. This collaboration seeks to leverage Arecor’s proprietary Arestat™ technology for formulation improvement to potentially enhance patient adherence and outcomes. Skye is currently conducting a Phase 2a clinical trial for nimacimab, with data expected in late 2025. The partnership underscores the companies' commitment to addressing unmet needs in metabolic health.
Read more →SKYE▼ -5.4%on this news
Preclinical Models Highlight Utility of Peripheral CB1 Inhibition
Skye presented a poster at ECO 2025 showcasing preclinical models that highlight the effectiveness of peripheral CB1 inhibition in promoting weight loss. The study utilized clinical pharmacokinetic and pharmacodynamic models to demonstrate these findings. This research suggests a potential therapeutic avenue for weight management.
Read more →SKYE▼ -5.4%on this newsshared move
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Skye Bioscience announced the grant of a non-qualified stock option award for 100,000 shares to a new non-executive employee under its 2024 Inducement Equity Incentive Plan. This employment inducement is in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at attracting new talent. The stock options are priced at $1.82 per share, equating to the closing stock price on May 7, 2025, and will vest over four years. Skye is actively developing therapies to enhance metabolic health, including a Phase 2 clinical trial for its drug nimacimab.
Read more →SKYE▼ -5.4%on this newsshared move
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
Skye Bioscience presented a groundbreaking clinical pharmacokinetic and pharmacodynamic model at the European Congress on Obesity, demonstrating that peripheral inhibition of CB1 is sufficient for achieving weight loss, contrary to prior assumptions about the necessity of central inhibition. The model indicates that nimacimab may offer a favorable therapeutic index due to minimal brain exposure, reducing neuropsychiatric adverse effects associated with other CB1 inhibitors. The findings are expected to significantly advance the understanding and development of therapeutics for obesity.
Read more →SKYESkye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
Skye Bioscience reported its financial results for the first quarter of 2025, highlighting advancements in its obesity treatment candidate, nimacimab. Preclinical studies indicate that nimacimab, when combined with tirzepatide, may enhance weight loss compared to tirzepatide alone. The company plans to present further data at the American Diabetes Association (ADA) conference in June 2025, with top-line results from its Phase 2a trial expected in late 2025. While the company retains a solid cash position, it also reported a significant net loss for the quarter, raising operational concerns.
Read more →SKYESkye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
Skye Bioscience, a clinical-stage biotechnology company, will announce its 2025 first quarter financial results on May 8th, 2025. A conference call to discuss the results is scheduled for the same day at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the live webcast through the Skye Investor Relations website, where a press release and additional financial materials will also be available. Skye is focused on innovative therapies for obesity through its Phase 2 clinical trial involving the antibody nimacimab.
Read more →SKYE2025 Stockholder Letter
Skye's 2025 Stockholder Letter outlines the company's achievements and the significance of CB1. It also presents the strategic direction for future growth. The letter is part of the 2025 proxy package, aimed at informing shareholders about the company's progress and plans.
Read more →SKYESkye Bioscience to Participate in May Investment and Medical Conferences
Skye Bioscience, a clinical-stage biotechnology company, announced its participation in several forthcoming healthcare conferences, including the Citizens Life Sciences Conference and the European Congress on Obesity. The company is focused on developing novel therapeutic pathways for obesity and metabolic health disorders, specifically through its Phase 2 clinical trial involving nimacimab. This trial assesses the combination of nimacimab with the GLP-1R agonist Wegovy. Webcasts of the presentations will be available on Skye's website.
Read more →SKYE▲ +5.9%on this news· ran to +18% by day 3shared move
Driving New Approaches in Obesity Drug Development
Skye Bioscience is advancing new methodologies in obesity drug development by concentrating on peripheral CB1 inhibition. This approach aims to enhance metabolic health, potentially leading to more effective treatments for obesity. The initiative reflects a significant shift in how obesity therapies may be developed in the future.
Read more →SKYE▲ +30.5%on this news
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
Skye Bioscience announced promising preclinical results for nimacimab, a CB1 antibody, showing over 30% weight loss in a murine model when used in combination with tirzepatide. The drug alone achieved a 23.5% weight reduction, suggesting comparable effectiveness to monlunabant and tirzepatide. The company is poised to further investigate the therapeutic potential of nimacimab, with Phase 2 clinical trial data expected in late 2025. The research indicates nimacimab's unique mechanism of action may offer distinct advantages over traditional small molecule CB1 inhibitors.
Read more →SKYE▼ -7.1%on this news· ran to +21% by day 1shared move
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
Skye Bioscience, Inc. is set to participate in the Piper Sandler Spring Biopharma Symposium on April 17th in Boston, MA to hold meetings with investors. The company is actively engaged in developing innovative therapeutics for metabolic disorders, specifically through its Phase 2 clinical trial of nimacimab for obesity. Their approach seeks to utilize biologic targets with human proof of concept, potentially leading to first-in-class therapies. However, the effectiveness of their strategies remains uncertain given the risks associated with clinical trials.
Read more →SKYE▲ +6.9%on this news
Chief Operating Officer: An Outlook on Work & Life
Tu Diep, the Chief Operating Officer of Skye Bioscience, shares insights on the importance of family values in the workplace. The article emphasizes a positive work-life balance and the significance of fostering a supportive company culture. Diep's perspective reflects a commitment to both professional and personal well-being.
Read more →SKYE▼ -11.8%on this news· ran to -33% by day 3
Transformative Weight Loss Drugs not Without Risks
A new class of weight loss drugs is significantly changing the landscape of obesity treatment. However, these transformative medications come with concerns regarding their safety and potential side effects. Additionally, questions about the implications of long-term use are being raised, highlighting the need for careful consideration.
Read more →SKYEObesity Through the Eyes of an Endocrinologist
The article titled 'Obesity Through the Eyes of an Endocrinologist' was published by Skye Bioscience on March 23, 2025. It appears to focus on the perspectives of an endocrinologist regarding obesity. However, the content does not provide specific insights or detailed information about the topic.
Read more →SKYE▼ -5.5%on this news· ran to +18% by day 3shared move
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Skye Bioscience has successfully completed enrollment in its Phase 2a CBeyond trial for nimacimab, a novel CB1 inhibitor aimed at treating obesity. The accelerated enrollment allows top-line data to be reported earlier than initially planned, with the trial's duration extended to enhance safety and efficacy evaluations. Financially, Skye reported a solid cash position projected to fund operations through Q1 2027, while also noting the increase in R&D expenses compared to the previous year. The CEO highlighted the clinical significance of nimacimab and its potential in the evolving obesity therapeutics market.
Read more →SKYESkye Bioscience to Announce 2024 Financial Results on March 20th, 2025
Skye Bioscience, a clinical-stage biotechnology company, announced it will host a conference call on March 20th, 2025, to discuss its fourth quarter and full-year financial results for 2024. The call will include a review of financial performance and insights into the company's ongoing development of nimacimab, a treatment for obesity. A press release detailing earnings will be available after market close on the same day, increasing accessibility for investors and stakeholders. Further information about Skye and its initiatives can be found on their investor relations website.
Read more →SKYEExpert Panel with Skye CEO + Obesity Specialist
At the South by Southwest conference, Skye CEO Punit Dhillon and Dr. Beverly Tchang discussed the importance of achieving sustainable weight loss. They highlighted recent scientific advancements and the potential of combination therapies, particularly focusing on the role of CB1 inhibition in obesity treatment.
Read more →SKYESXSW 2025 Pre-panel Chat Covers Broad Obesity-related Topics
Skye CEO Punit Dhillon and Dr. Beverly Tchang, a member of the Clinical Advisory Board, discussed their upcoming participation in the SXSW forum. They focused on weight loss and related topics in anticipation of their panel titled 'Weighing in on Weight Loss'. Their conversation highlights the significance of addressing obesity in public forums.
Read more →SKYECOO Reflects on the Challenges and Path of His Journey
Tu Diep, the COO of Skye Bioscience, shares insights into his career and the challenges faced during the clinical development of nimacimab. His reflections emphasize a deep passion for drug development and the strategic path taken to advance their lead asset. The article highlights the importance of dedication in overcoming obstacles in the biopharma industry.
Read more →SKYESkye Bioscience to Participate in SXSW Session on Obesity
Skye Bioscience, a clinical-stage biopharmaceutical company, announced that its CEO, Punit Dhillon, will participate in a panel session at the SXSW Conference. The session, titled 'Weighing in on Weight Loss Medicine,' will explore future strategies for obesity management beyond the commonly used GLP-1 drugs. Taking place on March 10, 2025, in Austin, TX, the event is part of SXSW's efforts to drive discussions on health and medtech advancements. Skye is focused on developing innovative therapies for metabolic health, including its Phase 2 clinical trial of nimacimab for obesity.
Read more →SKYESkye Bioscience to Present at TD Cowen Health Care Conference
Skye Bioscience, a clinical-stage biopharmaceutical company, announced that CEO Punit Dhillon will present a corporate overview at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025. The company focuses on treating obesity and metabolic health disorders via new therapeutic pathways and is currently conducting a Phase 2 clinical trial for its candidate drug nimacimab. A live webcast of the presentation will be available on the Skye Bioscience website.
Read more →SKYENew Weight Loss Drugs Aim to Save Muscle
The article discusses the development of new obesity drugs designed to reduce fat while preserving muscle mass, which is crucial for long-term health. Various companies are in competition to prove these drugs can offer functional benefits beyond simply aiding weight loss. This represents a significant advancement in obesity treatment strategies.
Read more →SKYESkye Bioscience Announces Participation in February Conferences
Skye Bioscience, a clinical-stage biopharmaceutical company, recently announced its participation in two upcoming investor conferences: the BIO CEO & Investor Conference and the Oppenheimer 35th Healthcare Life Sciences Conference. Skye aims to showcase its advancements in therapies targeting obesity and metabolic health disorders. The company is also conducting a Phase 2 clinical trial for its drug candidate nimacimab, which involves an assessment of its combination with a GLP-1R agonist. A live and archived webcast of the conferences will be accessible on Skye’s website.
Read more →SKYEThe Health Risks and Benefits of Weight-Loss Drugs
Recent data on GLP-1 weight loss drugs, including Wegovy and Ozempic, reveals significant benefits for heart and brain health. However, these drugs are also associated with certain risks, particularly gastrointestinal issues and other complications. The findings highlight the dual nature of these medications in weight management.
Read more →SKYEHow Can You Tell if Your Weight Is a Problem
The Lancet Commission report critiques the reliance on BMI as a sole indicator of weight-related health issues. It advocates for a broader evaluation of health impacts, including organ function, fat distribution, and risk markers. This shift aims to provide a more accurate assessment of when weight becomes a medical concern.
Read more →SKYECEO 2024 Year in Review
In a recent review, CEO Punit Dhillon outlined Skye's achievements in 2024, emphasizing the upcoming data release from the Phase 2 study of nimacimab aimed at weight loss. The company is also focused on its execution plans for 2025, indicating a proactive approach to future developments.
Read more →SKYESkye Bioscience Provides 2025 Look Ahead and Year in Review
Skye Bioscience, a clinical-stage biopharmaceutical company, aims to advance its Phase 2 trial for nimacimab, a unique peripherally-restricted CB1 inhibitor antibody targeting obesity treatment. The company has established a clear development plan and expects to share interim and topline data in 2025. Skye's leadership team has expanded to support these clinical ambitions, while risks associated with future testing and development efforts remain notable. The firm continues to engage with the scientific community at multiple upcoming conferences throughout 2025.
Read more →SKYEThe Understanding & Treatment of Obesity is Evolving
Dr. Beverly Tchang, a clinical advisor at Skye Bioscience, discusses the complexities of obesity and the advancements in treatment strategies. Her insights highlight the ongoing evolution in understanding obesity as a medical condition. The article emphasizes the importance of specialist knowledge in addressing obesity challenges.
Read more →SKYEThe Maturing Specialty of Obesity Management
Dr. Rekha Kumar, a clinical advisor at Skye Bioscience, shares her insights on obesity management. She discusses the current challenges and potential opportunities in treating obesity, highlighting the evolving specialty in this field. Her perspectives aim to enhance understanding and improve treatment strategies for obesity.
Read more →SKYESkye Bioscience to Present at J.P. Morgan Healthcare Conference
Skye Bioscience, a clinical-stage biopharmaceutical company, is set to present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The company focuses on developing new therapeutic pathways for obesity and related metabolic health disorders, with ongoing clinical trials for nimacimab, an innovative therapeutic agent. This presentation aims to inform about Skye's progress and strategies in pioneering treatments for metabolic conditions while navigating the risks inherent in drug development.
Read more →SKYE▼ -7.9%on this news
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
Skye Bioscience, Inc. has announced plans to participate in key healthcare investment conferences in December, including the Evercore HealthCONx and Citi Global Healthcare Conferences. The company is focusing on its clinical-stage development, particularly the Phase 2 trial of nimacimab, an antibody targeting obesity treatment. These events represent opportunities for Skye to engage with investors and showcase its therapeutic developments. However, the company acknowledges the risks associated with forward-looking statements related to its clinical trials and market unpredictability.
Read more →SKYESkye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Skye Bioscience, Inc. has surpassed 50% patient enrollment for its CBeyond™ Phase 2 trial, which evaluates nimacimab, a differentiated CB1 inhibitor, in overweight or obesity patients. The company anticipates interim data by Q2 2025 following the 26-week treatment period. Nimacimab has demonstrated a favorable safety profile, avoiding neuropsychiatric adverse events prevalent in other CB1 inhibitors. The trial's comprehensive design will assess various weight loss and health parameters.
Read more →SKYESkye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
Skye Bioscience reported its financial results for the third quarter of 2024, marking a pivotal transition as it launched its Phase 2 obesity clinical trial for nimacimab. The company highlighted promising preclinical data that showcased significant weight loss in a diet-induced obesity model. Skye's financial position remains strong, with cash and equivalents totaling $76.5 million, enough to fund operations through Q3 2027. However, the company continues to post net losses, though these have decreased notably compared to the same quarter last year.
Read more →SKYEKOLs Discuss Potential of Non-GLP1 Mechanism for Metabolic Rewiring
At the ObesityWeek November 2024 Satellite Event, key opinion leaders (KOLs) and Skye's management presented new insights into the potential of non-GLP1 mechanisms for metabolic rewiring. They discussed the differences between centrally and peripherally-driven CB1 inhibition. Additionally, data from Skye's diet-induced obesity model demonstrated promising dose-dependent weight loss outcomes.
Read more →SKYESkye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
Skye Bioscience has reported encouraging preliminary data on its CB1-inhibiting antibody, nimacimab, demonstrating significant weight loss and metabolic improvements in a diet-induced obesity model in mice. The results indicate that nimacimab achieved up to 16% weight loss and improved glucose tolerance without affecting the central nervous system, thereby minimizing the risk of neuropsychiatric adverse events. The study is described as a pivotal step in confirming the role of peripheral CB1 inhibition in weight management. Further preclinical data and insights will be shared at ObesityWeek.
Read more →SKYE▲ +6.1%on this newsshared move
Skye Bioscience to Announce Third Quarter 2024 Results
Skye Bioscience, Inc. has announced that it will release its financial results for the third quarter of 2024 after market close on November 7, 2024. Following the results, a conference call will be held to discuss them in detail. The company is currently focused on developing therapeutic solutions for metabolic health and is conducting a Phase 2 clinical trial for nimacimab, a treatment targeting obesity. The announcement reflects a commitment to stakeholder engagement and progress in clinical initiatives.
Read more →SKYESkye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
Skye Bioscience has appointed Paul Grayson as the new Chairman of the Board, effective October 25, 2024. This decision aims to enhance the independence and governance of the board to better guide the company's strategic direction. Grayson, who has extensive experience in the biotechnology field, will play a crucial role in overseeing the development of nimacimab, a therapeutic candidate for obesity and metabolic diseases. The CEO emphasized the importance of Grayson's leadership in achieving Skye's objectives during this pivotal phase of development.
Read more →SKYESkye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
Skye Bioscience, a clinical-stage biopharmaceutical company, announced its participation in several upcoming healthcare investment conferences in November. Notably, these include presentations at the Guggenheim, UBS, and Stifel Healthcare Conferences. The conferences will provide opportunities for 1x1 meetings and discussions about Skye's ongoing clinical research, particularly regarding its Phase 2 trial for nimacimab, an innovative treatment targeting obesity. These events are aimed at showcasing Skye's potential therapeutic advancements and connecting with investors.
Read more →SKYEBusiness of Biotech Podcast: Potential for Antibody CB1 Inhibitor
The podcast discusses Skye Bioscience's antibody-based CB1 inhibitor, highlighting its potential as a treatment for obesity. It emphasizes the promising aspects of this approach, particularly the reduced risk of neuropsychiatric side effects. The conversation explores the prospective role of this CB1 inhibitor in weight loss therapeutics.
Read more →SKYEAdvancing Nimacimab In The Anti-Obesity Market
The article discusses the progress of nimacimab as a potential weight loss treatment in the expanding anti-obesity market. It emphasizes the therapeutic advancements and the increasing interest in solutions for obesity management. The development of nimacimab could play a significant role in addressing obesity-related health issues.
Read more →SKYE▲ +11.1%on this news· ran to +28% by day 1
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Skye Bioscience has provided an update on its nimacimab clinical development, in the context of Novo Nordisk's Phase 2a data with monlunabant, a competing small-molecule CB1 inhibitor. While monlunabant achieved notable placebo-adjusted weight loss, it was associated with neuropsychiatric side effects, highlighting a key advantage of Skye's nimacimab, which has shown minimal central nervous system exposure in preclinical studies. Skye's Phase 2 trial for nimacimab aims for interim results in mid-2025, with the company emphasizing the safety and effectiveness of their large-molecule approach compared to existing small molecules.
Read more →SKYESkye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
Skye Bioscience has appointed Dr. Puneet S. Arora as Chief Medical Officer. Dr. Arora brings over 15 years of experience in clinical trials and metabolic diseases, which aligns with Skye's focus on developing treatments for metabolic health. His appointment coincides with the initiation of the Phase 2 CBeyond obesity trial for nimacimab, a novel CB1 inhibitor. The company's strategy aims to leverage Arora's expertise to advance clinical development in the metabolic field.
Read more →SKYE▲ +15.3%on this news
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
Skye Bioscience, a clinical-stage biopharmaceutical company, announced its participation in several upcoming healthcare investment conferences, including the Morgan Stanley Conference and Cantor Global Healthcare Conference. The company is focusing on developing next-generation molecules for metabolic health and has initiated a Phase 2 clinical trial for its treatment nimacimab in obesity. Skye's commitment to innovation in metabolic therapeutics positions it prominently in the healthcare space. However, the company has acknowledged inherent risks associated with forward-looking statements related to its strategies and clinical trials.
Read more →SKYESkye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
Skye Bioscience, Inc. has commenced screening patients for its Phase 2 CBeyond clinical trial of nimacimab, a CB1 inhibitor aimed at obesity treatment. The trial will evaluate the drug's efficacy in weight reduction while monitoring safety parameters and the maintenance of lean mass. Interim results are expected in Q2 2025, with final data due in Q4 2025. The trial not only focuses on weight loss but also explores gastrointestinal tolerability and psychiatric safety outcomes during the treatment period.
Read more →SKYESkye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Skye Bioscience, Inc. (SKYE) is currently under investigation by Bronstein, Gewirtz & Grossman, LLC, regarding potential claims from investors following the company's unsuccessful Phase 2a clinical trial of its SBI-100 Ophthalmic Emulsion. The trial did not achieve its primary goal of lowering intraocular pressure in patients with glaucoma. As a result, Skye intends to halt clinical development related to SBI-100 and refocus resources on its metabolic program. Subsequently, the company's stock experienced an 8.78% drop after the announcement.
Read more →SKYE▼ -9.4%on this newsshared move
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
Skye Bioscience reported its second quarter 2024 financial results, highlighting its planned Phase 2 clinical trial for nimacimab in obesity, set to begin in Q3 2024. The company has made strategic adjustments, including board appointments and a significant cash position that is expected to fund operations through the first half of 2027. However, Skye discontinued its SBI-100 OE program after disappointing trial results, leading to a reported net loss of $7.9 million.
Read more →SKYEEmpowered Patient Podcast: Discussing Fat Metabolism
CEO Punit Dhillon discusses a new anti-obesity drug that targets the CB1 receptor through the endocannabinoid system. This approach aims to shift the weight-loss paradigm from a focus on caloric restriction to addressing the underlying issues related to fat metabolism. The discussion highlights the potential for more effective weight management strategies.
Read more →SKYEObesity Specialists Weigh in on Need for New Anti-obesity Drugs
The article discusses the insights from obesity specialists and Skye management regarding the urgent need for new anti-obesity medications. It highlights the potential role of CB1 inhibition in addressing unmet treatment needs in obesity management. The publication serves as an introduction to Skye's 'Anatomy of Progress' series.
Read more →SKYESkye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
Skye Bioscience hosted a virtual KOL event to discuss its Nimacimab Phase 2 clinical trial design, focusing on obesity and sleep apnea. The CBeyond Phase 2 trial aims to enroll 120 patients to evaluate weight loss, safety, and metabolic changes, along with exploratory sleep endpoints in collaboration with Beacon Biosignals. The trial is set to begin screening in August 2024, with interim data expected in 2025. Skye highlights the potential of Nimacimab as a novel anti-obesity therapy compared to current treatments.
Read more →SKYE▲ +6.9%on this news
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
Skye Bioscience is set to host a virtual KOL event on July 24, 2024, focusing on 'Metabolic Rewiring with CB1 Inhibition'. Esteemed experts will discuss the treatment landscape for obesity and provide insights into Skye's clinical candidate, Nimacimab. This candidate acts as a peripheral CB1 inhibitor and aims to address significant medical needs related to obesity and metabolic diseases. The Phase 2 clinical trial for Nimacimab is expected to begin in Q3 2024, marking an important step for the company.
Read more →SKYE▲ +6.9%on this news
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
Skye Bioscience, Inc. has established a Clinical and Scientific Advisory Board to enhance the development of its lead candidate, Nimacimab, aimed at treating obesity. The board comprises notable experts in metabolic diseases who will offer strategic guidance as the drug prepares for a Phase 2 trial set to begin in the third quarter of 2024. Nimacimab is a pioneering monoclonal antibody that inhibits CB1 receptor signaling, offering potential benefits in treating obesity and related metabolic conditions.
Read more →SKYESkye Bioscience Appoints Dr. Karen Smith to Board of Directors
Skye Bioscience has appointed Dr. Karen Smith to its Board of Directors, enhancing the company's leadership with her significant biopharma experience. This appointment comes as the company prepares to advance its Nimacimab metabolic program, aiming to launch a Phase 2 clinical trial targeting obesity. Concurrently, two board members are resigning, effective August 1, 2024. Skye continues its strategic focus on therapeutic developments leveraging the endocannabinoid system.
Read more →SKYESkye Bioscience Added to Russell 2000 and Russell 3000 Indexes
Skye Bioscience, a clinical-stage biotechnology company, has been included in the Russell 2000 and Russell 3000 indexes, effective July 1, 2024. This inclusion is seen as a recognition of the company's recent achievements and is anticipated to increase visibility among investors. The company is also preparing for the Phase 2 clinical trial of its drug Nimacimab, aimed at addressing obesity and other medical conditions, set to launch in the third quarter of 2024.
Read more →SKYE▼ -6.2%on this news
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
Skye Bioscience, a clinical-stage biopharmaceutical company, will participate in the Piper Sandler Virtual Obesity Day on June 26, 2024. The event will feature presentations and discussions on obesity therapeutics, with involvement from key opinion leaders in the field. Skye is also preparing to initiate a Phase 2 clinical trial for its drug Nimacimab, which targets the endocannabinoid system, anticipated to begin in the third quarter of 2024.
Read more →SKYE▼ -8.8%on this news
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
Skye Bioscience has decided to discontinue its SBI-100 Ophthalmic Emulsion program after the Phase 2a clinical trial failed to meet its primary endpoint of significantly lowering intraocular pressure in patients with primary open-angle glaucoma. The company will redirect its resources to its metabolic program, with a Phase 2 obesity trial for Nimacimab set to begin in Q3 2024. Despite the setback in ophthalmology, Skye's cash runway has been extended into 2027, providing time to focus on new clinical opportunities.
Read more →SKYESkye Bioscience to Present at Jefferies Global Healthcare Conference
Skye Bioscience, Inc. is set to present at the Jefferies Global Healthcare Conference on June 5, highlighting its innovative programs aimed at treating obesity and glaucoma. CEO Punit Dhillon will provide insights into the company’s progress with Nimacimab, currently in a Phase 2 trial for obesity, and SBI-100 Ophthalmic Emulsion, which is being evaluated for glaucoma. Upcoming topline data for the glaucoma study is expected in Q2 2024, while the company also notes inherent risks in its future projections related to clinical outcomes and market conditions.
Read more →SKYE▼ -6.2%on this news
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
Skye Bioscience presented a novel library of synthetic cannabinoid-based compounds at the ARVO 2024 Annual Meeting, aiming to advance treatments for ocular diseases, specifically dry eye disease and chronic ocular pain. The company identified three lead compounds following rigorous testing on their effects on cannabinoid receptors related to these conditions. The presentation emphasized the potential of this new approach to address unmet medical needs in ocular health. Skye's ongoing efforts include plans for clinical trials for other cannabinoid therapies, indicating a commitment to developing innovative treatments.
Read more →SKYESkye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
Skye Bioscience, Inc. announced its participation in the ARVO 2024 Annual Meeting where it will present two posters on its innovative therapeutic research. The presentations will cover a Phase 1 study of a topical ocular CB1 agonist and a novel library of endocannabinoid agonists aimed at treating dry eye disease and chronic ocular pain. Skye's continued focus on leveraging the endocannabinoid system highlights its commitment to developing unique therapies in the biopharmaceutical sector. The company also has upcoming clinical trials for other potential treatments scheduled in the near future.
Read more →SKYE▼ -5.3%on this news
Skye Bioscience to Present at Upcoming Investment Conferences
Skye Bioscience, Inc. announced that its CEO and executive team will present their programs at upcoming investment conferences, focusing on treatments for obesity and glaucoma. They aim to highlight their drug candidates, including nimacimab and SBI-100 Ophthalmic Emulsion, both of which are in clinical trials. Nimacimab is set to enter Phase 2 trials in mid-2024, while data for the glaucoma treatment is expected in Q2 2024. These conferences present an opportunity for Skye to engage with potential investors and showcase their therapeutic advancements.
Read more →SKYE▲ +39.7%on this news
Skye Bioscience Uplists to The Nasdaq Global Market
Skye Bioscience, a clinical-stage biotechnology firm, has announced its uplisting to the Nasdaq Global Market, effective April 11, 2024. This move signifies a recognition of the company's recent achievements, including advancements in Phase 2 clinical trials focused on glaucoma and obesity. The company anticipates releasing top-line data from its glaucoma study shortly, while preparations for its obesity trial are set for the third quarter of 2024. The uplist is expected to enhance the company's visibility and liquidity in the investment community.
Read more →SKYE▲ +7.6%on this news
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
Skye Bioscience has announced the appointment of Dr. Annalisa Jenkins to its Board of Directors. Dr. Jenkins brings over 25 years of experience in the pharmaceutical and biotechnology sectors, having held significant leadership roles at various companies. The CEO of Skye expressed confidence in her ability to enhance the company's strategic direction in developing therapeutic drugs targeting obesity and ocular disorders. Skye is set to commence a Phase 2 clinical trial focused on obesity in mid-2024.
Read more →SKYE▲ +13.8%on this news· ran to +102% by day 3
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
Skye Bioscience has successfully completed the enrollment of 56 patients in a Phase 2a clinical trial for its SBI-100 Ophthalmic Emulsion, aimed at treating glaucoma and ocular hypertension. All participants have finished the study without early discontinuations due to adverse events, and topline data is expected by Q2 2024. The trial's rapid enrollment reflects a strong demand for new IOP-lowering therapies, supported by feedback from key opinion leaders. Preliminary results from prior clinical trials suggest SBI-100 is safe, well-tolerated, and shows promising efficacy in reducing intraocular pressure.
Read more →SKYE▲ +14.3%on this news
Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab
Skye Bioscience has announced its clinical development plan for nimacimab, a differentiated peripheral CB1 inhibitor targeting obesity and chronic kidney disease. The company has filed an Investigational New Drug application with the FDA for a Phase 2 clinical study, set to begin in the first half of 2024. Nimacimab has shown a promising safety and tolerability profile, avoiding central nervous system side effects characteristic of other CB1 inhibitors. The growing obesity epidemic presents a significant opportunity for nimacimab as a treatment option, potentially even in combination with other therapeutic mechanisms.
Read more →SKYESkye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
Skye Bioscience has treated the first patient in its Phase 2 trial for SBI-100 Ophthalmic Emulsion, designed to reduce intraocular pressure in glaucoma patients. The trial will evaluate the drug's efficacy and safety compared to placebo. Following promising results from Phase 1, the company plans to analyze preliminary data from 50% of enrolled patients in Q1 2024. The study aims to confirm the drug's therapeutic benefits while advancing its potential in treating ophthalmic disorders.
Read more →SKYE▼ -15.1%on this news· ran to -37% by day 3
Document Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody Acquisition of Bird Rock Bio builds Skye's position as a leading endocannabinoid system-focused pharmaceutical co
Skye Bioscience has successfully completed a $17 million financing round and acquired Bird Rock Bio, advancing its focus on endocannabinoid system therapies. The capital will support a Phase 2a glaucoma clinical trial for its lead candidate, SBI-100 Ophthalmic Emulsion, and the development of nimacimab, a novel CB1-inhibiting monoclonal antibody. Both products target significant unmet medical needs in glaucoma and chronic kidney disease and are expected to enter clinical trials in the near future. Skye aims to leverage this acquisition and funding to solidify its position in the pharmaceutical industry.
Read more →SKYESkye Bioscience Completes Drug Production for Phase 1 Clinical Study
San Diego, California, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer (“CMO”) th
Read more →SKYESkye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date
San Diego, California, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announces that it has filed its definitive proxy stateme
Read more →SKYE▲ +23%on this news
Skye Bioscience Reports that Emerald Health Therapeutics Shareholders Voted in Favor of Plan of Arrangement with Skye
San Diego, California, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the shareholders of Emerald Health Therapeut
Read more →SKYESkye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer
Skye advances Phase 2 clinical development plans alongside Phase 1 clinical development San Diego, California, July 21, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoi
Read more →SKYESkye Bioscience Updates Phase 1 Timeline
San Diego, California, July 20, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer (“CMO”) of
Read more →SKYESkye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups
New collaborations focused on building library of novel cannabinoid derivatives and small molecules capable of modulating endocannabinoid system San Diego, California, June 07, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutic
Read more →SKYE▲ +25%on this news
Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics
Arrangement is expected to fund Skye’s proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022 Preclinical studies have demonstrated potential advantages of Skye’s unique, patent-prote
Read more →SKYE▲ +6.9%on this news
Skye Bioscience Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation Published in Peer-Reviewed Journal
San Diego, California, May 05, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet need, announced th
Read more →SKYESkye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research
San Diego, California, April 28, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet need, has retain
Read more →SKYESkye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
San Diego, Calif, March 03, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has e
Read more →SKYE▲ +25.9%on this news
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
Initiation of Phase 1 clinical trial of SBI-100 ophthalmic nanoemulsion expected in the second quarter of 2022 SAN DIEGO, CA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic cannabinoid-d
Read more →SKYESkye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
SAN DIEGO, CA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced tha
Read more →SKYE▲ +9.1%on this news
Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022
SAN DIEGO, CA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat diseases with significant unmet need, issued today the following letter from Chief Exe
Read more →SKYE▼ -5.5%on this news
Skye Bioscience to Present at H.C. Wainwright BIOCONNECT Virtual Conference
SAN DIEGO, CA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will present a corpor
Read more →SKYESkye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD
Skye Bioscience Announces Promotion of Tu Diep, MSc to Chief Development Officer SAN DIEGO, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived mole
Read more →SKYESkye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360
SAN DIEGO, CA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced
Read more →SKYESkye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program
SAN DIEGO, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has formed
Read more →SKYESkye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development
SAN DIEGO, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has strengthened its management team with the appointment
Read more →SKYESkye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer
SAN DIEGO, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has appointed Kaitlyn Arsenault, CPA, as Chief Financial
Read more →SKYESkye Bioscience Announces Closing of $7.0 Million Registered Direct Offering
SAN DIEGO, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, today ann
Read more →SKYESkye Bioscience Announces $7.0 Million Registered Direct Offering
skye_ex991.htm EXHIBIT 99.1 Skye Bioscience Announces $7.0 Million Registered Direct Offering SAN DIEGO, CA, September 27, 2021 -- Skye Bioscience, Inc. (OTCQB: SKYE) ("SKYE" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived mo
Read more →SKYESkye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360
SAN DIEGO, CA, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, announced today its research partner, the University of
Read more →SKYESkye Bioscience Announces Special Virtual Investor Presentation
SAN DIEGO, CA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will host a special
Read more →SKYESkye Bioscience to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, CA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will be presenting at
Read more →SKYESkye Bioscience to Present at the H.C. Wainwright Ophthalmology Conference
SAN DIEGO, CA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that Karam Takhar, VP of Corpo
Read more →SKYESkye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies
THCVHS shows no signs of chromosomal or gene mutations in preclinical studies SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat disea
Read more →SKYESkye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors
skye_ex991.htm EXHIBIT 99.1 Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors SAN DIEGO, CA, July 25, 2021 -- Skye Bioscience, Inc. (OTCQB: SKYE) ("SKYE" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabi
Read more →SKYESkye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, both as Combination and Single Agent, in Preclinical Study
THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of 32.4% and maintains an average IOP reduction of 26.5% at 9 hours, significantly better than any single drug or combination tested THCVHS demonstrates superior IOP-low
Read more →SKYESkye Bioscience Completes CMC and GLP Production for THCVHS Lead Program
Novel glaucoma drug ready for next development phase - GLP toxicology study – on critical path to first human clinical trial Ongoing development of THCVHS includes near-term preclinical comparison with and in combination with leading glaucoma treatments and an assessment of neur
Read more →SKYESkye Bioscience to Present at Upcoming Investment Conferences in April
San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announ
Read more →SKYESkye Bioscience to Present at Benzinga Biotech Small Cap Conference
San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, annou
Read more →SKYESkye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment
San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, annou
Read more →SKYESkye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference
San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet
Read more →SKYESkye Bioscience to Participate in Investment Conferences in February
San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet n
Read more →SKYEEmerald Bioscience Raises approximately $7.0 Million in Upsized Registered Offering Long Beach, CA
embi_ex991.htm EXHIBIT 99.1 Emerald Bioscience Raises approximately $7.0 Million in Upsized Registered Offering Long Beach, CA, August 4, 2020 - Emerald Bioscience, Inc. (OTCQB: EMBI) ("Emerald"), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeuti
Read more →SKYEEmerald Bioscience Announces $2.0 Million Registered Direct Offering Long Beach, CA
Emerald Bioscience Announces $2.0 Million Registered Direct Offering Long Beach, CA, November 21, 2019 - Emerald Bioscience, Inc. (OTCQB: EMBI) ("Emerald"), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications,
Read more →SKYEEmerald Bioscience Secures "All Fields" Licenses for Cannabinoid Derivatives Developed by University of Mississippi Licenses permit Emerald to develop THC-prodrug and CBD-analog for any therapeutic indication by any rout
Emerald Bioscience Secures "All Fields" Licenses for Cannabinoid Derivatives Developed by University of Mississippi Licenses permit Emerald to develop THC-prodrug and CBD-analog for any therapeutic indication by any route of administration for human and veterinary Use Long Beac
Read more →SKYEDouglas Cesario Chief Financial Officer Email: doug@emeraldbio.life Phone: 949-336-3437 FORWARD LOOKING STATEMENTS This press release contains forward-looking statements, including statements regarding our product develo
Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments Name change reflects company's focus on advancing cannabinoid-based therapeutics as a member of the Emerald Group Company to trade on OTCQB under ticker EMBI
Read more →SKYENemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog Enhanced bioavailability could prove pivotal in providing neuroprotection in diseases of the retina Long Beach, Calif.
Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog Enhanced bioavailability could prove pivotal in providing neuroprotection in diseases of the retina Long Beach, Calif., March 4, 2019 (GLOBE NEWSWIRE) -- Nemus Bioscience, Inc. (OTCQB: N
Read more →SKYENemus Bioscience Announces that Emerald Health Sciences has Provided a Credit Facility of up to $20 Million and Adopted an Open Market Share Purchase Program of up to 10 Million Common Shares Avtar Dhillon, MD, appointed
Nemus Bioscience Announces that Emerald Health Sciences has Provided a Credit Facility of up to $20 Million and Adopted an Open Market Share Purchase Program of up to 10 Million Common Shares Avtar Dhillon, MD, appointed as Executive Chairman of Nemus Long Beach, CA, October 8
Read more →SKYEEmerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule Nemus Bioscience Receives $1,750,000 Private Placement to Help Advance Innovative
Emerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule Nemus Bioscience Receives $1,750,000 Private Placement to Help Advance Innovative Bio-engineered Cannabinoid Pipeline Costa Mesa, Calif.
Read more →SKYENemus Secures Emerald Health as Strategic Majority Investor to help Advance Clinical Development of Novel Cannabinoid-based Therapeutics Nemus Bioscience Receives $400,000 Funding under Convertible Bridge Loan and Closes
Nemus Secures Emerald Health as Strategic Majority Investor to help Advance Clinical Development of Novel Cannabinoid-based Therapeutics Nemus Bioscience Receives $400,000 Funding under Convertible Bridge Loan and Closes Initial $1,500,000 Private Placement Costa Mesa, Calif. (
Read more →SKYENemus Bioscience Announces Closing of Convertible Bridge Loan and Anticipated Equity Financing C osta Mesa, Calif. (
Nemus Bioscience Announces Closing of Convertible Bridge Loan and Anticipated Equity Financing Costa Mesa, Calif. (December 29, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS, "Nemus") today announced that it entered into agreements with Emerald Health Sciences Inc. ("Emerald"), in
Read more →SKYENemus Bioscience Announces $2,000,000 Series F Preferred Stock Financing Costa Mesa, Calif. (
Nemus Bioscience Announces $2,000,000 Series F Preferred Stock Financing Costa Mesa, Calif. (November 1, 2017) - NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced that it closed a Securities Purchase Agreement with certain purchasers for the sale of 2,000 shares of Series F P
Read more →SKYENEMUS Bioscience Provides Further Update on Previously Announced $20 Million Schneider Financing Costa Mesa, Calif. (
NEMUS Bioscience Provides Further Update on Previously Announced $20 Million Schneider Financing Costa Mesa, Calif. (October 13, 2017) NEMUS Bioscience, Inc. (OTCQB: NMUS) (the "Company") today announced a further update to its news release dated May 4, 2017 and July 11, 2017 wi
Read more →SKYEN emus Bioscience Announces $20 Million Series E Preferred Stock Financing Costa Mesa, Calif. (
Nemus Bioscience Announces $20 Million Series E Preferred Stock Financing Costa Mesa, Calif. (May 4, 2017) --- NEMUS Bioscience, Inc. (OTCQB: NMUS) (the "Company") today announced the signing of a private placement with an affiliate of Schneider Brothers Ltd, a global closed in
Read more →SKYENEMUS Bioscience Announces Closing of $1,200,000 Preferred Stock Financing
NEMUS Bioscience Announces Closing of $1,200,000 Preferred Stock Financing COSTA MESA, CA - January 10, 2017 - NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced the closing of its Preferred Stock financing for gross proceeds of $1,200,000. Roth Capital Partners acted as the e
Read more →SKYENemus Bioscience Announces Preferred Stock Financing Costa Mesa, Calif. (
Nemus Bioscience Announces Preferred Stock Financing Costa Mesa, Calif. (December 29, 2016) - NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced that it entered into a Securities Purchase Agreement with certain purchasers for the sale of up to 1,500 shares of Series D Preferre
Read more →SKYENEMUS Bioscience Announces Closing of $500,000 Preferred Stock Financing
NEMUS Bioscience Announces Closing of $500,000 Preferred Stock Financing COSTA MESA, CA - October 27, 2016 - NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced the closing of its Preferred Stock financing for gross proceeds of $500,000. ROTH Capital Partners acted as the exclu
Read more →SKYENEMUS Bioscience Announces $500,000 Preferred Stock Financing
NEMUS Bioscience Announces $500,000 Preferred Stock Financing COSTA MESA, CA - October 26, 2016 - NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced that it entered into a Securities Purchase Agreement with certain purchasers for the sale of 500 shares of Preferred Stock for g
Read more →SKYESETTLEMENT AND RELEASE OF CLAIMS nmus_ex101.htm EXHIBIT 10.1
SETTLEMENT AND RELEASE OF CLAIMS nmus_ex101.htm EXHIBIT 10.1
Read more →SKYENEMUS Bioscience Appoints Dr. Brian Murphy as CEO Costa Mesa, CA
NEMUS Bioscience Appoints Dr. Brian Murphy as CEO Costa Mesa, CA - August 25, 2015 - NEMUS Bioscience, Inc. (OTCQB: NMUS). The NEMUS Board of Directors has elected to promote Dr. Brian S. Murphy to serve as its Chief Executive Officer (CEO) of the Company effective immediately.
Read more →SKYENEMUS Bioscience Announces $5M Series B Financing Funding to finance development of NB1111 for the treatment of glaucoma
NEMUS Bioscience Announces $5M Series B Financing Funding to finance development of NB1111 for the treatment of glaucoma COSTA MESA, CA - August 20, 2015 - NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced that it entered into a Securities Purchase Agreement with certain pur
Read more →SKYENEMUS Bioscience Announces Closing of $5.0 Million Series B Financing Funding to finance development of NB1111 for the treatment of glaucoma
NEMUS Bioscience Announces Closing of $5.0 Million Series B Financing Funding to finance development of NB1111 for the treatment of glaucoma COSTA MESA, CA - August 20, 2015 - NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced the closing of its Series B Convertible Preferred
Read more →SKYENEMUS BIOSCIENCE ANNOUNCES APPOINTMENT OF DOUGLAS S. INGRAM, FORMER PRESIDENT OF ALLERGAN, TO ITS BOARD OF DIRECTORS Former President of Allergan is appointed as Vice Chairman Costa Mesa, CA - June 1st, 2015 - NEMUS Bios
NEMUS BIOSCIENCE ANNOUNCES APPOINTMENT OF DOUGLAS S. INGRAM, FORMER PRESIDENT OF ALLERGAN, TO ITS BOARD OF DIRECTORS Former President of Allergan is appointed as Vice Chairman Costa Mesa, CA - June 1st, 2015 - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced the appointment of Do
Read more →SKYENEMUS BIOSCIENCE, INC. AUDIT COMMITTEE CHARTER I. Purpose The purpose of the Audit Committee (the "Committee") is to oversee the accounting and financial reporting processes of the Company and the audits of the financial
NEMUS BIOSCIENCE, INC. AUDIT COMMITTEE CHARTER The purpose of the Audit Committee (the "Committee") is to oversee the accounting and financial reporting processes of the Company and the audits of the financial statements of the Company. The Committee's responsibilities are lim
Read more →SKYENEMUS BIOSCIENCE ANNOUNCES APPOINTMENT OF THOMAS A. GEORGE, CFO of DECKERS BRANDS, TO ITS BOARD OF DIRECTORS Thirty-year financial veteran will assume Audit Committee Chair Responsibilities Costa Mesa, CA
NEMUS BIOSCIENCE ANNOUNCES APPOINTMENT OF THOMAS A. GEORGE, CFO of DECKERS BRANDS, TO ITS BOARD OF DIRECTORS Thirty-year financial veteran will assume Audit Committee Chair Responsibilities Costa Mesa, CA - January 12, 2015 - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced the a
Read more →SKYENEMUS BALANCE SHEETS ASSETS June 30
June 30, December 31, 2014 2013 2012 Current assets Cash and cash equivalents $ 528,494 $ - $ - Prepaid expenses and other current assets 16,029 - - Total assets $ 544,523 $ - $ - June 30, December 31, 2014 2013 2012 Current
Read more →Competitive Position
How SKYE ranks across every disease it competes inCompetitive Position is a premium feature
See how SKYE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial